Stefan Hantel

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 11.6K citations · Full text

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher et al. · The Lancet · 2007 · 1.1K citations

Thrombosis, Venous Disease, Venous Thrombosis +13

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Bengt I. Eriksson, O.E. Dahl, Nadia Rosencher et al. · Journal of Thrombosis and Haemostasis · 2007 · 983 citations · Full text

Total Knee Replacement, Thrombosis, Venous Disease +8

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Bernard Zinman, David Fitchett et al. · Diabetes Care · 2017 · 721 citations

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

Ola Dahl, Michael H. Huo, Andreas Kurth et al. · Thrombosis and Haemostasis · 2011 · 398 citations